Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

The role of Proteus mirabilis cell wall features in biofilm formation.

Czerwonka G, Guzy A, Kałuża K, Grosicka M, Dańczuk M, Lechowicz Ł, Gmiter D, Kowalczyk P, Kaca W.

Arch Microbiol. 2016 Nov;198(9):877-84. doi: 10.1007/s00203-016-1249-x. Epub 2016 Jun 4.

2.

Angel(®) Catheter use for pulmonary embolism prophylaxis in a polytrauma patient.

Serednicki W, Dobrowolska E, Kałuża K, Kopacz M, Wordliczek J.

Injury. 2015;46(6):1167-70. doi: 10.1016/j.injury.2015.03.013. Epub 2015 Mar 16.

PMID:
25890862
3.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.

4.

A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood.

Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, Fischer JA, Klostermann S, Endl J, Kopetzki E, Pashine A, Siewe B, Kaluza B, Platzer J, Offner S.

PLoS One. 2014 Feb 4;9(2):e86184. doi: 10.1371/journal.pone.0086184. eCollection 2014.

5.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.

6.

Improving the outcome of adoptive cell transfer by targeting tumor escape.

Kaluza KM, Vile R.

Oncoimmunology. 2013 Jan 1;2(1):e22059.

7.

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C.

PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.

8.

Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, Vile RG.

Cancer Res. 2012 Sep 15;72(18):4753-64. doi: 10.1158/0008-5472.CAN-12-0600. Epub 2012 Jul 26.

9.

Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.

Kaluza KM, Kottke T, Diaz RM, Rommelfanger D, Thompson J, Vile R.

Hum Gene Ther. 2012 Oct;23(10):1054-64. doi: 10.1089/hum.2012.030. Epub 2012 Aug 13.

10.

Allosteric antibody inhibition of human hepsin protease.

Koschubs T, Dengl S, Dürr H, Kaluza K, Georges G, Hartl C, Jennewein S, Lanzendörfer M, Auer J, Stern A, Huang KS, Packman K, Gubler U, Kostrewa D, Ries S, Hansen S, Kohnert U, Cramer P, Mundigl O.

Biochem J. 2012 Mar 15;442(3):483-94. doi: 10.1042/BJ20111317.

PMID:
22132769
11.

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Kaluza KM, Thompson JM, Kottke TJ, Flynn Gilmer HC, Knutson DL, Vile RG.

Int J Cancer. 2012 Aug 15;131(4):844-54. doi: 10.1002/ijc.26447. Epub 2011 Nov 30.

12.

Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.

Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, Kottke T, Thompson J, Melcher A, Vile R.

Hum Gene Ther. 2011 Nov;22(11):1343-53. doi: 10.1089/hum.2010.216. Epub 2011 Apr 11.

13.

Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, Strome S, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Dec;16(12):1910-8. doi: 10.1038/mt.2008.212. Epub 2008 Sep 30.

14.

Magnetic cells for cancer therapy: adopting magnets for cell-based cancer therapies.

Kaluza K, Vile RG.

Gene Ther. 2008 Dec;15(23):1511-2. doi: 10.1038/gt.2008.139. Epub 2008 Aug 21. No abstract available.

PMID:
18719530
15.

Expression-level dependent activation of recombinant human parathyroid hormone/parathyroid hormone-related peptide receptor: effect of human parathyroid hormone (1-34), (1-31), and (28-48).

Tonn O, Kriegbaum S, Braitmaier A, Schäfer W, Esswein A, Dony C, Kaluza K, Honold K.

J Recept Signal Transduct Res. 2000 May-Aug;20(2-3):133-51.

PMID:
10994650
16.

[Burnout syndrome in women in surgery].

Pothmann M, Kaluza K, Mann F.

Langenbecks Arch Chir Suppl Kongressbd. 1997;114:734-6. German.

PMID:
9574255
17.

Heat-labile uracil-DNA glycosylase: purification and characterization.

Sobek H, Schmidt M, Frey B, Kaluza K.

FEBS Lett. 1996 Jun 10;388(1):1-4.

18.

BpuAI, a novel BbsI and BbvII isoschizomer from Bacillus pumilus recognizing 5'-GAAGAC-3'.

Pogge von Strandmann R, Städtler P, Walter T, Frey B, Kaluza K, Hengstenberg W, Schmitz G.

Nucleic Acids Res. 1992 Sep 11;20(17):4664. No abstract available.

19.

AspEI, a novel Eam11051 isoschizomer from Aureobacterium species recognizing 5'-GACnnn/nnGTC-3'.

Frey B, Kaluza K, Auer J, Stratidakis I, Rina M, Bouriotis V, Schmitz G.

Nucleic Acids Res. 1992 Jul 25;20(14):3782. No abstract available.

20.

Ssp5230I, a novel isoschizomer of AatII from Streptomyces recognizing 5'-GACGT/C-3'.

Knoblich IM, Sellmann E, Kaluza K, Frey B, Auer J, Schmitz GG, Westermann P.

Nucleic Acids Res. 1992 May 11;20(9):2378. No abstract available.

21.

Bsp423I, a novel isoschizomer of BbvI from Bacillus recognizing 5'-GCAGC-3'.

Sellmann E, Knoblich IM, Kaluza K, Frey B, Schmitz GG, Westermann P.

Nucleic Acids Res. 1992 May 11;20(9):2377. No abstract available.

22.

RleAI: a novel class-IIS restriction endonuclease from Rhizobium leguminosarum recognizing 5'-CCCACA(N)12-3' 3'-GGGTGT(N)9-5'.

Vesely Z, Müller A, Schmitz GG, Kaluza K, Jarsch M, Kessler C.

Gene. 1990 Oct 30;95(1):129-31. No abstract available.

PMID:
2253885
23.

MamI, a novel class-II restriction endonuclease from Microbacterium ammoniaphilum recognizing 5'-GATNN decreases NNATC-3'.

Striebel HM, Schmitz GG, Kaluza K, Jarsch M, Kessler C.

Gene. 1990 Jul 2;91(1):95-100.

PMID:
2401411
24.

SfuI, a novel AsuII isoschizomer from Streptomyces fulvissimus recognizing 5'-TT/CGAA-3'.

Veitinger S, Schmitz GG, Kaluza K, Jarsch M, Braun V, Kessler C.

Nucleic Acids Res. 1990 Jun 11;18(11):3424. No abstract available.

25.

BmyI, a novel SduI isoschizomer from Bacillus mycoides recognizing 5'-GDGCH/C-3'.

Wagner E, Schmitz GG, Kaluza K, Jarsch M, Götz F, Kessler C.

Nucleic Acids Res. 1990 May 25;18(10):3088. No abstract available.

26.

SgrAI, a novel class-II restriction endonuclease from Streptomyces griseus recognizing the octanucleotide sequence 5'-CR/CCGGYG-3' [corrected].

Tautz N, Kaluza K, Frey B, Jarsch M, Schmitz GG, Kessler C.

Nucleic Acids Res. 1990 May 25;18(10):3087. No abstract available. Erratum in: Nucleic Acids Res 1990 Aug 25;18(16):4991.

27.

McrI: a novel class-II restriction endonuclease from Micrococcus cryophilus recognizing 5'-CGRY/CG-3'.

Brensing-Küppers J, Reischl U, Schmitz GS, Kaluza K, Jarsch M, Kessler C.

FEBS Lett. 1990 May 21;264(2):218-22.

28.

Long-term effects of a complex behavioral treatment of essential hypertension.

Lehnert H, Kaluza K, Vetter H, Losse H, Dorst K.

Psychosom Med. 1987 Jul-Aug;49(4):422-30.

PMID:
3615770
29.

[Long-term effect and prognostic criteria of a behavior therapy program in essential hypertension].

Kaluza K, Lehnert H, Losse H, Dorst K.

Psychother Psychosom Med Psychol. 1986 Jun;36(6):179-86. German. No abstract available.

PMID:
3526379
30.

Activation of the Bradyrhizobium japonicum nifH and nifDK operons is dependent on promoter-upstream DNA sequences.

Alvarez-Morales A, Betancourt-Alvarez M, Kaluza K, Hennecke H.

Nucleic Acids Res. 1986 May 27;14(10):4207-27.

31.
32.

[Clinico-psychologic therapy of essential hypertension].

Dorst KG, Kaluza K, Lehnert H, Schmidt H, Vetter H, Losse H.

Med Welt. 1984 Feb 3;35(5):144-5. German. No abstract available.

PMID:
6700427
33.

In Rhizobium japonicum the nitrogenase genes nifH and nifDK are separated.

Kaluza K, Fuhrmann M, Hahn M, Regensburger B, Hennecke H.

J Bacteriol. 1983 Aug;155(2):915-8.

34.

Psychological control of essential hypertension.

Dorst K, Kaluza K, Lehnert H, Schmidt H, Losse H.

Act Nerv Super (Praha). 1982;Suppl 3(Pt 2):437-43. No abstract available.

PMID:
6763835
35.

Regulation of nitrogenase messenger RNA synthesis and stability in Klebsiella pneumoniae.

Kaluza K, Hennecke H.

Arch Microbiol. 1981 Sep;130(1):38-43.

PMID:
6171234

Supplemental Content

Loading ...
Support Center